Refine by
Anxiety Articles & Analysis: Older
123 news found
Regular intake has been demonstrated to reduce symptoms of depression and anxiety, enhance fetal brain development, and lower heart disease risks by managing cholesterol and blood pressure levels. ...
Psychiatric drug development is a crucial aspect of mental health treatment, as it involves the development of medications that can effectively treat various psychiatric disorders such as depression, anxiety, schizophrenia, and others. The process of antipsychiatric drug development typically involves several stages, including identifying potential drug targets, conducting ...
At best, most of us tolerate needles. Whether a vaccine, an IV drip, or a blood draw, we can talk ourselves through it with the knowledge that it is for the greater good and will only cause temporary discomfort. On the other side of the spectrum, there are people with such an intense fear of needles that they are considered to have a phobia, trypanophobia to be precise. Many articles have been ...
CanaQuest Medical Corp (“CanaQuest” or the “Company”) (OTC: CANQF), is pleased to announce strategic additions to its executive team with expertise in conducting clinical trials and US FDA drug approval success. The team plans to effectively navigate the regulatory approval process for Drug Candidate, CQ-001 (cannabidiol + proprietary API composition), to treat rare ...
These concerns include compromised memory as well as the correlation between anxiety and ...
Have you heard of the sensory phenomenon known as ASMR for sleep? ASMR stands for autonomous sensory meridian response, a condition, experience, or phenomenon that helps you fall asleep. As a form of parasthesia (a group or series of sensations felt in the skin), ASMR is perceived as a pleasant experience that is characterized by a tingling sensation in the neck and scalp areas that are ...
Thanksgiving is a time when families gather around the table to give thanks for their blessings, share a delicious meal, and create memories. It’s a holiday that encourages us to reflect on what we are grateful for and appreciate the people and opportunities in our lives. While Thanksgiving is traditionally a family-centric holiday, it’s also an excellent opportunity for businesses to ...
NHL Alumni Association (NHLAA), NEEKA Health Canada("NEEKA"),and CanaQuest Medical Corp ("CanaQuest") are pleased to announce a transformative study partnership that will investigate the efficacy of Mentanine® as a potential treatment to reduce anxiety in former NHL ...
Anxiety and depression affect millions of individuals worldwide, leading to a significant burden on public health and impacting overall quality of life. ...
The Scientific Difference - based on pre-clinical trial results at Western University THC vs Mentabinol® For many users, THC causes: Memory impairment and possible long-term cognitive side effects, Depression-like and schizophrenia-related symptoms, Anxiety and hyperactive activity, Schizophrenia due to gene vulnerability. ...
Canaquest Medical Corp (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced that it has been awarded the Best Global Medical Cannabinoid Development Company 2023, in its eighth annual Healthcare and Pharmaceutical ...
The Company is focused on treating neurological conditions, such as epilepsy, anxiety, depression, and Post Traumatic Stress Disorder "PTSD", including addiction. ...
The PTR platform has the opportunity to be used for delivery of medications in other large markets, including anxiety (CTx-2103 in development), insomnia, depression, bipolar disorder, Parkinson’s disease, xerostomia (dry mouth), migraine, and hypothyroidism. ...
Portal’s needle-free delivery technology is derived from research at MIT and enables the administration of high viscosity biologic drugs with less discomfort and without the anxiety of handling needles. Real time tracking and reporting sets a new standard for monitoring adherence and potentially improving patient outcomes. ...
The discussion will address the current unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD), as well as the expansion of Cingulate’s PTR platform into the anxiety therapeutic area. Dr. Schaffer will also provide a company overview. ...
The discussion will address the current unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD), as well as the expansion of Cingulate’s PTR platform into the anxiety therapeutic area. Dr. Schaffer will also provide a company overview. ...
” Additional secondary endpoints showed further evidence of the potential impact of zuranolone on the reduction of other PPD related symptoms, including anxiety in these patients. Treatment with zuranolone was shown to significantly improve symptoms of anxiety at Days 3, 8, 15, and 45 (p less than 0.05, at all time points) when compared to placebo as ...
About Precision Timed Release™ (PTR™) Platform Technology and OralogiK™ Cingulate is developing ADHD and anxiety disorder product candidates capable of achieving true once-daily dosing using the Company’s innovative PTR™ drug delivery platform technology. ...
With an initial focus on the treatment of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR™ technology may be employed to develop future product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City. About Societal CDMO Societal CDMO (NASDAQ: SCTL) is a bi-coastal contract development and ...
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced data from an oral presentation at Neurocritical Care Society’s (NCS) 20th Annual Meeting held in San Antonio, Texas on October 17 – 21, 2022 on the possible role of gammaCore (nVNS) in the acute treatment of Traumatic Brain Injury (TBI). The presentation is being given by Dr. Afshin ...